Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

← catalyst calendar

NCT05407324 · readout ≤ 72 d

Sponsored by Corcept Therapeutics (industry) · CORT — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

279estimated

Sites

Countries

Belgium, Canada, France +7

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-11-15

actual

When the study began enrolling

Primary completion

Oct 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Nov 2027

estimated

The whole study's end, after follow-up

First posted

2022-06-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-16

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Amyotrophic Lateral Sclerosis

Interventions

Drug: Dazucorilant 300 mg — also filed as CORT113176
Drug: Dazucorilant 150 mg — also filed as CORT113176
Other: Placebo
Drug: Dazucorilant — also filed as CORT113176

Primary outcomes

what the primary-completion date above is the date OF

Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score.

measured Baseline to Week 24

Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, AEs by severity, and deaths due to AEs

measured Baseline to Week 24

Incidence of treatment-emergent AEs and SAEs

measured Baseline up to Week 12

Incidence of treatment-emergent AEs leading to dose interruptions, dose reductions, and/or discontinuations of study drug

measured Baseline up to Week 12

Permalink · CORT's whole pipeline · Catalyst calendar · Every registered study · What changed